"CD27 Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds to CD27 ANTIGEN. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; and DENDRITIC CELLS where it plays a role in stimulating the proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES.
Descriptor ID |
D053282
|
MeSH Number(s) |
D12.644.276.374.750.030 D12.776.395.092 D12.776.467.374.750.030 D12.776.543.550.170 D23.529.374.750.030
|
Concept/Terms |
CD27 Ligand- CD27 Ligand
- Ligand, CD27
- Antigens, CD70
- CD70 Antigens
- Tumor Necrosis Factor Ligand Superfamily Member 7
- CD27L Protein
- CD70 Antigen
- Antigen, CD70
- TNF Superfamily, Member 7
|
Below are MeSH descriptors whose meaning is more general than "CD27 Ligand".
Below are MeSH descriptors whose meaning is more specific than "CD27 Ligand".
This graph shows the total number of publications written about "CD27 Ligand" by people in this website by year, and whether "CD27 Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2008 | 1 | 0 | 1 |
2010 | 0 | 1 | 1 |
2011 | 2 | 0 | 2 |
2014 | 0 | 1 | 1 |
2019 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
2022 | 0 | 1 | 1 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD27 Ligand" by people in Profiles.
-
Overview of CD70 as a Potential Therapeutic Target for Osteosarcoma. J Immunol. 2023 10 01; 211(7):1067-1072.
-
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 2023 02 13; 41(2):340-355.e6.
-
CD70 is a potential target biomarker in peripheral T-cell lymphomas. Histopathology. 2022 08; 81(2):272-275.
-
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021 07 29; 138(4):318-330.
-
LGALS3 is connected to CD74 in a previously unknown protein network that is associated with poor survival in patients with AML. EBioMedicine. 2019 Jun; 44:126-137.
-
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2014 Dec; 32(6):1246-57.
-
Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61.
-
T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood. 2011 Apr 21; 117(16):4304-14.
-
Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types. J Leukoc Biol. 2010 Jul; 88(1):69-78.
-
Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res. 2008 Oct 01; 14(19):6171-80.